Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Publication date: May 2020Source: The Lancet Diabetes & Endocrinology, Volume 8, Issue 5Author(s): Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto, Srikanth Deenadayalan, Andrea Navarria, Keiji Nishijima, Yutaka Seino, Y Fukushima, Y Hamamoto, A Hisatomi, Y Ide, S Inoue, T Kawada, H Kim, A Kiyosue, K Matoba, O Matsuoka, H Nishimura, M Noguchi, T Osonoi
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research